Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

EXEL Exelixis Inc

34,13

-0,87 (-2,49%)

Última atualização: 17:30:09

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

02/14/2025

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

10/30/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for S. Gail Eckhardt

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Exelixis.

Exelixis (NASDAQ:EXEL)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Exelixis.

Notícias Exelixis Inc

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
Sábado, 15 de Fevereiro de 2025 (3 dias atrás) • Business Wire

Form 144 - Report of proposed sale of securities
Sexta, 14 de Fevereiro de 2025 (4 dias atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Sexta, 14 de Fevereiro de 2025 (4 dias atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Sexta, 14 de Fevereiro de 2025 (4 dias atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Sexta, 14 de Fevereiro de 2025 (4 dias atrás) • Edgar (US Regulatory)

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
Quinta, 13 de Fevereiro de 2025 (5 dias atrás) • Business Wire

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Terça, 11 de Fevereiro de 2025 (7 dias atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Terça, 11 de Fevereiro de 2025 (7 dias atrás) • Edgar (US Regulatory)

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
Terça, 11 de Fevereiro de 2025 (7 dias atrás) • Business Wire

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
Terça, 28 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
Sábado, 25 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
Sexta, 24 de Janeiro de 2025 (4 semanas atrás) • Business Wire

Mais Notícias de Exelixis Inc

PT Vale Indonesia TBK (PK)

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições